First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer

Huang, ACC; Huang, CH; Ju, JS; Chiu, TH; Tung, PH; Wang, CC; Liu, CY; Chung, FT; Fang, YF; Guo, YK; Kuo, CHS; Yang, CT

Kuo, CHS (corresponding author), Chang Gung Univ, Div Thorac Oncol, Dept Thorac Med, Chang Gung Mem Hosp,Coll Med, 199 Tun Hwa Nr Rd, Taipei 333, Taiwan.; Kuo, CHS (corresponding author), Chang Gung Mem Hosp, Canc Ctr, Thorac Oncol Unit, Taoyuan, Taiwan.; Kuo, CHS (corresponding author), Imperial Coll London, Data Sci Inst, Dept Comp, London, England.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021; 13 ():

Abstract

Background: There are limited comparisons of first- and second-generation EGFR tyrosine kinase inhibitors (TKIs) in large, real-world cohorts of non-s......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索